z-logo
open-access-imgOpen Access
The Efficacy of Topical 0.03% Tacrolimus Dermatologic Ointment in Treatment of Vernal Keratoconjunctivitis
Author(s) -
Muhammad Adnan,
Amena Masrur,
Furqan Ahmed Khan,
Ali Tayyab
Publication year - 2021
Publication title -
life and science
Language(s) - English
Resource type - Journals
eISSN - 2708-2970
pISSN - 2521-0475
DOI - 10.37185/lns.1.1.142
Subject(s) - medicine , tacrolimus , vernal keratoconjunctivitis , dermatology , antihistamine , palpebral fissure , ketotifen , topical medication , surgery , ophthalmology , anesthesia , transplantation , asthma , glaucoma
Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernalkeratoconjunctivitis.Study Design: Cross-sectional.Place and Duration of Study: The study was conducted at Eye Donors Association Hospital, Wah Cantonmentfrom August 2019 to January 2020.Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were includedin this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornixonce at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine(0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief.The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinicalsigns were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized gradingsheet.Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baselinescores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dotsafter 8 weeks of treatment.Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment ofvernal kerato-conjunctivitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom